HRP20180804T1 - Inhibitori dnk-pk - Google Patents
Inhibitori dnk-pk Download PDFInfo
- Publication number
- HRP20180804T1 HRP20180804T1 HRP20180804TT HRP20180804T HRP20180804T1 HR P20180804 T1 HRP20180804 T1 HR P20180804T1 HR P20180804T T HRP20180804T T HR P20180804TT HR P20180804 T HRP20180804 T HR P20180804T HR P20180804 T1 HRP20180804 T1 HR P20180804T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- cancer
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/056,560 US9376448B2 (en) | 2012-04-24 | 2013-10-17 | DNA-PK inhibitors |
| EP14800181.1A EP3057959B1 (en) | 2013-10-17 | 2014-10-17 | Dna-pk inhibitors |
| PCT/US2014/061033 WO2015058031A1 (en) | 2013-10-17 | 2014-10-17 | Dna-pk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180804T1 true HRP20180804T1 (hr) | 2018-08-10 |
Family
ID=51932571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180804TT HRP20180804T1 (hr) | 2013-10-17 | 2014-10-17 | Inhibitori dnk-pk |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3057959B1 (OSRAM) |
| JP (1) | JP6374959B2 (OSRAM) |
| CN (1) | CN105636958B (OSRAM) |
| AU (1) | AU2014337208B2 (OSRAM) |
| BR (1) | BR112016008423B1 (OSRAM) |
| CA (1) | CA2927392C (OSRAM) |
| DK (1) | DK3057959T3 (OSRAM) |
| ES (1) | ES2671354T3 (OSRAM) |
| HR (1) | HRP20180804T1 (OSRAM) |
| HU (1) | HUE037516T2 (OSRAM) |
| LT (1) | LT3057959T (OSRAM) |
| PL (1) | PL3057959T3 (OSRAM) |
| PT (1) | PT3057959T (OSRAM) |
| RS (1) | RS57306B1 (OSRAM) |
| SI (1) | SI3057959T1 (OSRAM) |
| TR (1) | TR201807411T4 (OSRAM) |
| WO (1) | WO2015058031A1 (OSRAM) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37756B1 (fr) | 2012-06-13 | 2018-09-28 | Hoffmann La Roche | Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane |
| SI2900669T1 (sl) | 2012-09-25 | 2019-12-31 | F. Hoffmann-La Roche Ag | Derivati heksahidropirolo(3,4-C)pirola in sorodne spojine kot zaviralci avtotaksina (ATX) in kot zaviralci tvorbe lizofosfatidne kisline (LPA) za zdravljenje npr. bolezni ledvic |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| UA118201C2 (uk) | 2013-11-26 | 2018-12-10 | Ф. Хоффманн-Ля Рош Аг | НОВИЙ ОКТАГІДРОЦИКЛОБУТА[1,2-c;3,4-c']ДИПІРОЛ-2-ІЛ |
| EA032357B1 (ru) | 2014-03-26 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
| CA2937616A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| PE20180479A1 (es) | 2015-09-04 | 2018-03-07 | Hoffmann La Roche | Nuevos derivados de fenoximetilo |
| JP6845230B2 (ja) | 2015-09-24 | 2021-03-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物 |
| EP3353178B1 (en) | 2015-09-24 | 2021-07-14 | F. Hoffmann-La Roche AG | Bicyclic compounds as dual atx/ca inhibitors |
| AU2016328535A1 (en) | 2015-09-24 | 2017-11-09 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| EP3353176B1 (en) | 2015-09-24 | 2022-01-19 | F. Hoffmann-La Roche AG | Bicyclic compounds as atx inhibitors |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| JP2019529475A (ja) * | 2016-09-27 | 2019-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法 |
| CN110392679B (zh) | 2017-03-16 | 2023-04-07 | 豪夫迈·罗氏有限公司 | 可用作双重atx/ca抑制剂的杂环化合物 |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
| MA49126B1 (fr) * | 2017-05-18 | 2021-10-29 | Idorsia Pharmaceuticals Ltd | Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2 |
| WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| SI3625224T1 (sl) | 2017-05-18 | 2021-11-30 | Idorsia Pharmaceuticals Ltd | N-substituirani indolni derivati |
| WO2018210988A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as pge2 receptor modulators |
| WO2019100062A1 (en) | 2017-11-20 | 2019-05-23 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| WO2019136320A1 (en) | 2018-01-05 | 2019-07-11 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| US12121524B2 (en) | 2018-01-17 | 2024-10-22 | Vertex Pharmaceuticals Incorporated | DNA-PK inhibitors |
| KR20200110687A (ko) | 2018-01-17 | 2020-09-24 | 버텍스 파마슈티칼스 인코포레이티드 | 유전체 편집 효율을 증가시키기 위한 퀴녹살리논 화합물, 조성물, 방법 및 키트 |
| ES3038913T3 (en) | 2018-03-20 | 2025-10-15 | Icahn School Med Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| EP3906028A4 (en) * | 2018-12-31 | 2022-10-12 | Icahn School of Medicine at Mount Sinai | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE |
| CN112300126A (zh) * | 2019-07-31 | 2021-02-02 | 山东轩竹医药科技有限公司 | 杂环类dna-pk抑制剂 |
| CN112574179B (zh) * | 2019-09-29 | 2022-05-10 | 山东轩竹医药科技有限公司 | Dna-pk抑制剂 |
| CN112574211B (zh) * | 2019-09-29 | 2022-06-14 | 山东轩竹医药科技有限公司 | 杂环类激酶抑制剂 |
| JP7428806B2 (ja) * | 2019-12-31 | 2024-02-06 | 成都百裕制薬股▲ふん▼有限公司 | プリン誘導体および医薬におけるその使用 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7179912B2 (en) * | 2000-09-01 | 2007-02-20 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| EP1678147B1 (en) * | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| EP1901747A2 (en) * | 2005-05-25 | 2008-03-26 | Ingenium Pharmaceuticals AG | Pyrimidine-based cdk inhibitors for treating pain |
| KR101101675B1 (ko) * | 2006-10-02 | 2011-12-30 | 노파르티스 아게 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| KR20130016244A (ko) * | 2010-03-10 | 2013-02-14 | 인게니움 파르마코이티칼스 게엠베하 | 단백질 키나아제의 억제제 |
| MX371331B (es) * | 2012-04-24 | 2020-01-27 | Vertex Pharma | Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk). |
-
2014
- 2014-10-17 CN CN201480057118.6A patent/CN105636958B/zh active Active
- 2014-10-17 TR TR2018/07411T patent/TR201807411T4/tr unknown
- 2014-10-17 EP EP14800181.1A patent/EP3057959B1/en active Active
- 2014-10-17 RS RS20180605A patent/RS57306B1/sr unknown
- 2014-10-17 HR HRP20180804TT patent/HRP20180804T1/hr unknown
- 2014-10-17 HU HUE14800181A patent/HUE037516T2/hu unknown
- 2014-10-17 PT PT148001811T patent/PT3057959T/pt unknown
- 2014-10-17 AU AU2014337208A patent/AU2014337208B2/en active Active
- 2014-10-17 BR BR112016008423-3A patent/BR112016008423B1/pt active IP Right Grant
- 2014-10-17 CA CA2927392A patent/CA2927392C/en active Active
- 2014-10-17 PL PL14800181T patent/PL3057959T3/pl unknown
- 2014-10-17 WO PCT/US2014/061033 patent/WO2015058031A1/en not_active Ceased
- 2014-10-17 SI SI201430733T patent/SI3057959T1/en unknown
- 2014-10-17 ES ES14800181.1T patent/ES2671354T3/es active Active
- 2014-10-17 DK DK14800181.1T patent/DK3057959T3/en active
- 2014-10-17 LT LTEP14800181.1T patent/LT3057959T/lt unknown
- 2014-10-17 JP JP2016523925A patent/JP6374959B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PT3057959T (pt) | 2018-06-04 |
| BR112016008423A2 (OSRAM) | 2017-08-01 |
| BR112016008423B1 (pt) | 2022-02-22 |
| AU2014337208B2 (en) | 2018-05-24 |
| JP6374959B2 (ja) | 2018-08-15 |
| ES2671354T3 (es) | 2018-06-06 |
| HUE037516T2 (hu) | 2018-09-28 |
| RS57306B1 (sr) | 2018-08-31 |
| DK3057959T3 (en) | 2018-06-06 |
| JP2016533366A (ja) | 2016-10-27 |
| WO2015058031A1 (en) | 2015-04-23 |
| CN105636958A (zh) | 2016-06-01 |
| SI3057959T1 (en) | 2018-07-31 |
| EP3057959B1 (en) | 2018-02-28 |
| CA2927392A1 (en) | 2015-04-23 |
| CA2927392C (en) | 2021-11-09 |
| PL3057959T3 (pl) | 2018-08-31 |
| EP3057959A1 (en) | 2016-08-24 |
| CN105636958B (zh) | 2018-01-05 |
| TR201807411T4 (tr) | 2018-06-21 |
| LT3057959T (lt) | 2018-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180804T1 (hr) | Inhibitori dnk-pk | |
| JP2016533366A5 (OSRAM) | ||
| BR112015008365A2 (pt) | composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente | |
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| MX2015012432A (es) | Inhibidores piridinicos de la cinasa cdk9. | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| HRP20250250T1 (hr) | Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji | |
| CO6680717A2 (es) | Derivados de quinolina y quinoxalina como inhibidores de cinasa | |
| TR201819653T4 (tr) | Karaciğer kanserinin tedavisinde kullanılmaya yönelik organik bileşik. | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| SI3069720T1 (sl) | Farmacevtski sestavek, ki vsebuje derivate glutarimida, in njegova uporaba za zdravljenje eozinofilnih bolezni | |
| HRP20190537T1 (hr) | Farmaceutske kombinacije koje sadrže inhibitor b-raf, inhibitor egfr i po izboru inhibitor pi3k-alfa | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| IL244902A0 (en) | Derivatives of aminochroman, aminothiochroman and amino-1,2,3,4-tetrahydroquinoline, pharmaceutical compositions containing them and their use in treatment | |
| HRP20200662T1 (hr) | Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak | |
| CY1122387T1 (el) | Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| IL269710A (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers | |
| MX369952B (es) | Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1. | |
| MX2015011614A (es) | Derivados de pirrolidina, composiciones farmaceuticas que los contienen, y su uso en terapia. | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| MX2015012386A (es) | Inhibidores de la cinasa cdk9. | |
| JP2014504636A5 (OSRAM) |